UK markets open in 2 hours 19 minutes

Genmab A/S (GNMSF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
426.42+4.34 (+1.03%)
At close: 3:27PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close422.08
Open425.98
Bid0.00 x 0
Ask0.00 x 0
Day's range415.58 - 427.00
52-week range299.08 - 500.92
Volume163
Avg. volume604
Market cap28.326B
Beta (5Y monthly)0.60
PE ratio (TTM)70.61
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet

    COPENHAGEN, Denmark & NORTH CHICAGO, Ill., September 09, 2021--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). The full manuscript is a

  • Globe Newswire

    Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference

    Media ReleaseCopenhagen, Denmark, 27 August, 2021 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference at 8:00 AM EDT / 2:00 PM CEST on September 9, 2021. A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content About

  • Globe Newswire

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; August 17, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,370 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 200 shares at DKK 220.40,1,100 shares at DKK 466.20,200 shares at DKK 623.50,750 shares at DKK 636.50,478 shares